GLP-1 Users Face Fourfold Higher Risk of Nail Detachment

The first controlled study of GLP-1 drugs and nail health found detachment in 39% of users versus 9% of similar non-users.

The first controlled study of GLP-1 receptor agonists and nail health found that nail detachment was more than four times as common among people taking the drugs as among comparable people with obesity or type 2 diabetes who had never taken them. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, the research compared 575 GLP-1 users with 1,329 control participants recruited across France, the United States, Brazil and Mexico. Until now, evidence linking these therapies to nail changes had been limited largely to isolated adverse-event reports.

The scale of the gap caught researchers off guard: 39% of GLP-1 users reported nail detachment compared with just 9% of controls, while two-thirds (66%) reported at least one nail disorder against 53% of the comparison group. Nail discoloration showed an even starker divide, affecting 46% of users versus 17% of controls. Just as striking, the differences persisted even when researchers restricted the analysis to participants who had actually lost weight, suggesting rapid weight reduction alone cannot explain the pattern. 'Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal,' said study author Dr. Charles Taïeb.

The study cannot establish that the drugs caused the nail changes. Around half of users reported experiencing nail problems before starting treatment, and adjusting for dermatological conditions and nutritional deficiencies weakened some associations, though detachment and discoloration still remained roughly two to three times more frequent among users after adjustment. Dr. Taïeb cautioned that 'not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.' Both studies were cross-sectional and relied on patient-reported symptoms, meaning recall bias and heightened attention to bodily changes among people on a widely discussed medication remain possible confounders.

A companion study of the same participants found hair and scalp changes were also significantly more common among GLP-1 users. Unusual hair loss was reported by 50% of users versus 34% of controls, loss of hair volume or density affected 42% versus 19%, and hair loss beginning only after treatment started was more than twice as common (26% versus 12%). Scalp redness was roughly three times more frequent in users. Crucially, hair loss rarely occurred in isolation — most cases came with itching, redness or scaling, a pattern study author Dr. Bruno Halioua says suggests an inflammatory component that goes beyond the classic shedding seen after rapid weight loss, and which may be treatable.

According to the Daily Mail, UK regulators have logged 940 hair-loss reports linked to tirzepatide — Mounjaro's active ingredient — since the start of 2025, plus at least 312 tied to Wegovy and Ozempic. Researchers proposed possible mechanisms including micronutrient deficiencies in iron, zinc and biotin, and the body diverting resources away from non-essential structures like nails.

The researchers stress awareness rather than alarm. Dr. Halioua emphasized that these changes are frequent, usually benign, and are not a reason to stop an effective treatment on one's own initiative — anyone who notices hair shedding, an itchy or red scalp, or nail changes should mention it to their doctor rather than discontinue therapy.